Literature DB >> 17699761

Distinct ErbB-2 coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles.

Babette Schade1, Sonya H L Lam, Daniela Cernea, Virginie Sanguin-Gendreau, Robert D Cardiff, Boonim L Jung, Michael Hallett, William J Muller.   

Abstract

ErbB-2 overexpression and amplification occurs in 15% to 30% of human invasive breast carcinomas associated with poor clinical prognosis. Previously, we have shown that four ErbB-2/Neu tyrosine-autophosphorylation sites within the cytoplasmic tail of the receptor recruit distinct adaptor proteins and are sufficient to mediate transforming signals in vitro. Two of these sites, representing the growth factor receptor binding protein 2 (Grb2; Neu-YB) and the Src homology and collagen (Shc; Neu-YD) binding sites, can induce mammary tumorigenesis and metastasis. Here, we show that transgenic mice bearing the two other ErbB-2 autophosphorylation sites (Neu-YC and Neu-YE) develop metastatic mammary tumors. A detailed comparison of biological profiles among all Neu mutant mouse models revealed that Neu-YC, Neu-YD, and Neu-YE mammary tumors shared similar pathologic and transcriptional features. By contrast, the Neu-YB mouse model displayed a unique pathology with a high metastatic potential that correlates with a distinct transcriptional profile, including genes that promote malignant tumor progression such as metalloproteinases and chemokines. Furthermore, Neu-YB tumor epithelial cells showed abundant intracellular protein level of the chemokine CXCL12/SDF-1alpha, which may reflect the aggressive nature of this Neu mutant mouse model. Taken together, these findings indicate that activation of distinct Neu-coupled signaling pathways has an important impact on the biological behavior of Neu-induced tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17699761     DOI: 10.1158/0008-5472.CAN-06-4724

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response.

Authors:  Josie Ursini-Siegel; Sean Cory; Dongmei Zuo; William R Hardy; Elton Rexhepaj; Sonya Lam; Babette Schade; Karin Jirstrom; Eva Bjur; Ciriaco A Piccirillo; David Denardo; Lisa M Coussens; Donal J Brennan; William M Gallagher; Morag Park; Tony Pawson; Michael Hallett; William J Muller
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

Review 2.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

3.  ErbB-2 signals through Plexin-B1 to promote breast cancer metastasis.

Authors:  Thomas Worzfeld; Jakub M Swiercz; Mario Looso; Beate K Straub; Kishor K Sivaraj; Stefan Offermanns
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

4.  Fc-DIRECTED ANTIBODY CONJUGATION OF MAGNETIC NANOPARTICLES FOR ENHANCED MOLECULAR TARGETING.

Authors:  Robabeh Rezaeipoor; Renu John; Steven G Adie; Eric J Chaney; Marina Marjanovic; Amy L Oldenburg; Stephanie A Rinne; Stephen A Boppart
Journal:  J Innov Opt Health Sci       Date:  2009-10-01

5.  β-arrestin deficiency protects against pulmonary fibrosis in mice and prevents fibroblast invasion of extracellular matrix.

Authors:  Alysia Kern Lovgren; Jeffrey J Kovacs; Ting Xie; Erin N Potts; Yuejuan Li; W Michael Foster; Jiurong Liang; Eric B Meltzer; Dianhua Jiang; Robert J Lefkowitz; Paul W Noble
Journal:  Sci Transl Med       Date:  2011-03-16       Impact factor: 17.956

6.  Loss of one Tgfbr2 allele in fibroblasts promotes metastasis in MMTV: polyoma middle T transgenic and transplant mouse models of mammary tumor progression.

Authors:  Wei Bin Fang; Iman Jokar; Anna Chytil; Harold L Moses; Ty Abel; Nikki Cheng
Journal:  Clin Exp Metastasis       Date:  2011-03-04       Impact factor: 5.150

7.  Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer.

Authors:  B L Allen-Petersen; C J Carter; A M Ohm; M E Reyland
Journal:  Oncogene       Date:  2013-03-11       Impact factor: 9.867

8.  ShcA signalling is essential for tumour progression in mouse models of human breast cancer.

Authors:  Josie Ursini-Siegel; W Rod Hardy; Dongmei Zuo; Sonya H L Lam; Virginie Sanguin-Gendreau; Robert D Cardiff; Tony Pawson; William J Muller
Journal:  EMBO J       Date:  2008-02-14       Impact factor: 11.598

9.  Signaling through ShcA is required for transforming growth factor beta- and Neu/ErbB-2-induced breast cancer cell motility and invasion.

Authors:  Jason J Northey; Juliann Chmielecki; Elaine Ngan; Caterina Russo; Matthew G Annis; William J Muller; Peter M Siegel
Journal:  Mol Cell Biol       Date:  2008-03-10       Impact factor: 4.272

10.  The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice.

Authors:  Mark P Fereshteh; Maddalena T Tilli; Sung Eun Kim; Jianming Xu; Bert W O'Malley; Anton Wellstein; Priscilla A Furth; Anna T Riegel
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.